miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer.

Clin Cancer Res

Authors' Affiliations: Cancer Genetics, Kolling Institute of Medical Research; Department of Endocrinology; Department of Anatomical Pathology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Surgery, Bankstown Hospital, Bankstown, New South Wales, Australia; South Western Sydney Clinical School, University of New South Wales; Endocrine Surgical Unit, University of Sydney; Department of Surgery, Liverpool Hospital, Sydney, New South Wales, Australia; Endocrine Surgical Unit, University of California Los Angeles; and Division of Hematology and Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California.

Published: December 2009

PURPOSE: Adrenocortical adenomas are common, whereas adrenocortical carcinomas are rare. Discriminating between benign and malignant adrenocortical tumors using conventional histology can be difficult. In addition, adrenocortical carcinomas generally have poor prognosis and limited treatment options. MicroRNAs are short noncoding RNAs that are involved in regulation of gene transcription. EXPERIMENTAL DESIGN: To identify microRNAs involved in the pathogenesis of adrenocortical tumors, expression profiling of microRNAs was done on a cohort of 22 adrenocortical carcinomas, 27 adrenocortical adenomas, and 6 normal adrenal cortices. RESULTS: Twenty-three microRNAs were found to be significantly differentially expressed between adrenocortical carcinomas and adrenocortical adenomas. miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas compared with adrenocortical adenomas. This result was further validated in an external cohort of six adrenocortical carcinomas and four adrenocortical adenomas. Using Kaplan-Meier analysis, downregulation of miR-195 and upregulation of miR-483-5p in adrenocortical carcinomas were significantly associated with poorer disease-specific survival. CONCLUSIONS: These findings indicate that deregulation of microRNAs is a recurring event in human adrenocortical carcinomas and that aberrant expression of miR-195 and miR-483-5p identifies a subset of poorer prognosis adrenocortical carcinomas. (Clin Cancer Res 2009;15(24):7684-92).

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1587DOI Listing

Publication Analysis

Top Keywords

adrenocortical carcinomas
36
adrenocortical adenomas
20
adrenocortical
17
carcinomas adrenocortical
12
carcinomas
9
mir-195 mir-483-5p
8
poor prognosis
8
prognosis adrenocortical
8
adrenocortical tumors
8
cohort adrenocortical
8

Similar Publications

Editorial: Rare forms of pediatric adrenal disorders: beyond congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Front Endocrinol (Lausanne)

December 2024

Centre for Endocrinology, William Harvey Research Institute, Barts & the London School of Medicine & Dentistry, Queen Mary, University of London, London, United Kingdom.

View Article and Find Full Text PDF

Oncocytic adrenal cortical carcinoma (ACC) is a rare malignant adrenal cortical tumor with limited documented case reports. Herein, a 65-year-old female patient presented with a large, solid adrenal mass. A diagnosis of oncocytic ACC was rendered with the following tumor characteristics: The tumor entirely consists of diffuse sheets of polygonal cells with bizarre nuclear atypia and deeply eosinophilic cytoplasm.

View Article and Find Full Text PDF

Background: Kinectin 1 () is a membrane protein involved in intracellular organelle motility. However, the role of in human pan-cancer lacks systematic analysis and evaluation. The aim of this study is to evaluate the expression profile and clinical value in human cancers by performing a pan-cancer analysis of .

View Article and Find Full Text PDF

Adrenocortical carcinomas (ACCs) are rare and aggressive malignancies of adrenal cortex, associated with largely unknown mechanisms of biological development and poor prognosis. Currently, mitotane is the sole approved drug for treating advanced adrenocortical carcinomas (ACCs) and is being utilized more frequently as postoperative adjuvant therapy. Although it is understood that mitotane targets the adrenal cortex and disrupts steroid production, its precise mechanism of action requires further exploration.

View Article and Find Full Text PDF

Background/objectives: Adrenocortical tumors (ACTs), including adrenocortical adenoma (ACA) and carcinoma (ACC), represent 0.3-0.4% of pediatric tumors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!